The acquisition follows the US Federal Trade Commission’s early termination of the waiting period required by US antitrust law. With the completion of the acquisition, Reliant’s cardiovascular medicines join the GlaxoSmithKline (GSK) portfolio in the US. These include Lovaza, an FDA-approved treatment for adult patients with very high levels of triglycerides.
In addition to Lovaza, three other cardiovascular products marketed by Reliant will join the GSK portfolio in the US. They are DynaCirc CR (isradipine) and InnoPran XL (propanolol HCl), for treatment of high blood pressure, and Rythmol SR (propafenone), for treatment of abnormal heart rhythms, or arrhythmia.